BUSINESSCNBC TOP
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
Innovent Biologics' shares increased by 10% following a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines, with the pact valued up to $10.5 billion.
Related Signal
Adjacent reporting
- China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn
- Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
- IREN shares pop 13% on AI infrastructure deal with Nvidia
- IREN shares jumps on $1.6 billion Dell deal to expand AI cloud business
- Intel Stock Hits All-Time High After Preliminary Chip Deal With Apple
- China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials